Cardio-renal-metabolic (CRM) diseases represent a complex and interconnected spectrum of conditions that encompass cardiovascular diseases (CVDs), renal diseases, and metabolic disorders like diabetes and obesity. The relationship among these conditions is multifaceted and bidirectional, with each disease acting as a risk factor for the others, thereby creating a vicious cycle of morbidity and mortality.
Studies reveal that a strong underlying mechanism connects these diseases with shared risk factors and common pathophysiological pathways leading to compounding the multimorbid effect of this condition. We look at the genetic predispositions, environmental variables, and lifestyle decisions that affect how CRM diseases start and advance. We also examine how endothelial dysfunction, oxidative stress, and inflammation contribute to the aggravation of the CRM illness cascade.
We also look at the clinical ramifications and difficulties associated with CRMD, highlighting the significance of a patient-centered approach. The combination of metabolic, renal, and cardiovascular illness requires multi-pathway targeted integrated treatment approaches. In addition, we investigate new diagnostic techniques and cutting-edge therapy approaches that may help individuals with CRMD. Through a comprehensive analysis of the relationship between cardiovascular, renal, and metabolic illnesses, this work seeks to direct future investigations and provide guidance for therapeutic management.
Finally, we suggest a multidisciplinary approach to the management of CRMD, encouraging joint care amongst primary care physicians, cardiologists, nephrologists, and endocrinologists. The knowledge gathered from this investigation may eventually lead to improved patient outcomes and a decrease in the prevalence of cardiorenal metabolic illness worldwide.
Main article link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650723/
References:
- Andreadi A., Bellia A., Daniele N.D., Meloni M., Lauro R., Della-Morte D., Lauro D. The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases. Curr. Opin. Pharmacol. 2022;62:85–96. doi: 10.1016/j.coph.2021.11.010. [PubMed] [CrossRef] [Google Scholar]
- Zhang R., Mamza J.B., Morris T., Godfrey G., Asselbergs F.W., Denaxas S., Hemingway H., Banerjee A. Lifetime risk of cardiovascular-renal disease in type 2 diabetes: A population-based study in 473,399 individuals. BMC Med. 2022;20:63. [PMC free article] [PubMed] [Google Scholar]
- Tomás-Simó P., D’Marco L., Romero-Parra M., Tormos-Muñoz M.C., Sáez G., Torregrosa I., Estañ-Capell N., Miguel A., Gorriz J.L., Puchades M.J. Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients. Int. J. Environ. Res. Public Health. 2021;18:7806. doi: 10.3390/ijerph18157806. [PMC free article] [PubMed] [CrossRef] [Google Scholar]